GlassScriptPhysician profile
Lindsay Jo Orris
NPI 1225263833
$4,050.11
in general payments reported to CMS, 2019-2025
26 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $177 · 2021: $210 · 2022: $482 · 2023: $641 · 2024: $864 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.37 |
| Education | $282.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.17 | 2019-2025 | |
| Janssen Biotech, INC. | $615.11 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $592.60 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Ucb, INC. | $276.18 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.87 | 2019-2025 | Cyltezo, Ofev |
| Novartis Pharmaceuticals Corporation | $225.10 | 2019-2025 | |
| Sobi, INC | $149.04 | 2025 | |
| Pfizer INC. | $133.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $130.15 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $125.72 | 2019-2024 | Taltz, Zepbound |
| Radius Health, INC. | $105.29 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $102.81 | 2022-2025 | Actemra, Gazyva |
| E.R. Squibb & Sons, L.L.C. | $87.64 | 2019-2025 | Orencia |
| Mckesson Specialty Care Distribution, LLC | $81.43 | 2020 | |
| Genzyme Corporation | $80.89 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $72.88 | 2022-2025 | Hadlima |
| Horizon Therapeutics Plc | $62.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $54.45 | 2022-2024 | Saphnelo |
| Teva Pharmaceuticals USA, INC. | $41.70 | 2023-2024 | Truxima |
| Aurinia Pharma U.S., INC. | $41.22 | 2021-2022 | |
| Celgene Corporation | $39.86 | 2019 | |
| Fresenius Kabi USA, LLC | $31.38 | 2023-2024 | Idacio |
| Almatica Pharma LLC | $28.98 | 2025 | Teriparatide |
| Johnson & Johnson Health Care Systems INC. | $18.74 | 2019 | |
| Sandoz INC. | $13.44 | 2024 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Orris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.